Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: rjm2 who wrote (1144)	9/20/2003 11:29:48 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

There are two ways for me to answer: 1. There are no insiders. Smile, be happy; or 2. Yeah, it bugs me. The "true" insiders are the employees that got passed off to OSI. They were the ones who were either feeding BS or good molecules to Goddard. If they were good molecules and IF the royalty (Solvay/OSI, first to market) pays anything above expenses to keep the attorneys paid (if not, Glass really, really, really screwed up), you'd think that those ex-employees would be buying hand over fist, based on leverage and the cash cushion of downside. One note..... I don't believe that anybody knew about the Solvay molecule having transitioned into clinical trials, and it seems that we HAVE had a buyer since we found that news. Second note.... for all we know, SLV320 has entered clinical testing and already failed. Flying blind, and, yes, it bugs me that dispersed insiders have not approached Glass/Paige/Broach/Icahn to make a deal, particularly during the recent crisis of liquidity.